Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis after haploidentical peripheral blood stem cell transplantation
ACTRN12617000151336Phase 2Recruiting
- Sponsor
- St Vincent's Hospital Sydney
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of cyclophosphamide in graft-versus-host disease (GVHD) (2 arms), sponsored by St Vincent's Hospital Sydney. Primary endpoint: Disease-free survival. Started Aug 2015; status: recruiting.
02
Drugs
cyclophosphamide
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on ACTRN12617000151336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000151336.